title: Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes.
authors.forename: Rabea
authors.initials: R
authors.lastname: Asleh
authors.forename: Nina S
authors.initials: NS
authors.lastname: Levy
authors.forename: Gheorge
authors.initials: G
authors.lastname: Doros
authors.forename: Tina
authors.initials: T
authors.lastname: Costacou
authors.forename: Jennifer G
authors.initials: JG
authors.lastname: Robinson
authors.forename: Shany
authors.initials: S
authors.lastname: Blum
authors.forename: Hagit
authors.initials: H
authors.lastname: Goldenstein
authors.forename: William E
authors.initials: WE
authors.lastname: Boden
authors.forename: Debra L
authors.initials: DL
authors.lastname: Simmons
authors.forename: Megan A
authors.initials: MA
authors.lastname: Lacy
authors.forename: George
authors.initials: G
authors.lastname: Grunberger
authors.forename: Todd J
authors.initials: TJ
authors.lastname: Anderson
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Levy
mesh_terms: D003920:Diabetes Mellitus / Q000235:genetics* / Q000378:metabolism*; D005838:Genotype; D006242:Haptoglobins / Q000235:genetics*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000378:metabolism; D009525:Niacin / Q000627:therapeutic use*
chemical_list: D006242:Haptoglobins; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D009525:Niacin